Cholera toxin chimera and its use as a staph vaccine
The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus -specific polypeptide.
1. A method of generating an immune response in a mammal comprising administering to the mammal a composition comprising a chimeric protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, or an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, and S. aureus specific polypeptide antigen comprising iron-regulated surface determinant A (IsdA) of SEQ ID NO: 4 as present within the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
2. The method of claim 1 wherein the composition is a single polypeptide.
3. The method of claim 1 , wherein the chimeric protein comprises the amino acid sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6.
4. The method of claim 1 , wherein the chimeric protein is assembled from a first polypeptide and a second polypeptide that are covalently linked.
5. The method of claim 1 , wherein the chimeric protein is a fusion protein.
6. The method of claim 1 , wherein the mammal is selected from the group consisting of, a cow, a cat, a dog, and a horse.
7. The method of claim 1 , wherein the administration of the composition is selected from the group consisting of intranasal administration, intramuscular administration, subcutaneous administration, and any combination thereof.
8. A method of immunizing a cow against S. aureus comprising administering to the cow a chimeric protein comprising:
an adjuvant polypeptide of SEQ ID NO: 2 or a polypeptide with at least 90% sequence identity thereto and a polypeptide of SEQ ID NO: 3 or a polypeptide with at least 90% sequence identity thereto and
S. aureus specific iron-regulated surface determinant A (IsdA) polypeptide of SEQ ID NO: 4 as present within the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
9. The method of claim 8 , wherein the administration of the chimeric protein is selected from the group consisting of intranasal administration, intramuscular administration, subcutaneous administration, and any combination thereof.
10. The method of claim 8 , wherein the chimeric protein is assembled from a first polypeptide and a second polypeptide that are non-covalently linked.
11. The method of claim 10 , wherein the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 6.
12. The method of claim 10 , wherein the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3.
13. The method of claim 8 , wherein the chimeric protein comprises the amino acid sequence set forth in SEQ ID NO: 5.
14. The method of claim 1 , wherein said mammal is a human and said chimeric protein is purified.